Uzman Dr. İzzet DOĞAN

Yayın Ağı

Makaleler 61

1. Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study

Ozgun A., Mustafayev F. N. A., Dogan I., Vatansever S., Eryilmaz M. K., ERDOĞAN A. P., et al.

Molecular and Clinical Oncology , cilt.22, sa.6, 2025 (ESCI) Sürdürülebilir Kalkınma

2. Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer

Khanmammadov N., Dogan I., Okay N. S., KHISHIGSUREN B., AZİZY A., Saip P., et al.

Minerva obstetrics and gynecology , cilt.77, sa.2, ss.112-118, 2025 (ESCI, Scopus)

3. The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data

Khanmammadov N., Ferhatoglu F., PAKSOY N., Dogan İ., KHISHIGSUREN B., Nizam N., et al.

Medicine (United States) , cilt.104, sa.6, 2025 (SCI-Expanded, Scopus)

4. Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine

Khanmammadov N., Doǧan I., KHISHIGSUREN B., AZİZY A., Saip P., AYDINER A.

Medicine (United States) , cilt.104, sa.6, 2025 (SCI-Expanded, Scopus)

5. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

6. Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients

Dogan I., Yıldız A., Ahmed M. A., Vatansever S.

Indian Journal of Surgical Oncology , cilt.15, sa.3, ss.489-494, 2024 (ESCI, Scopus)

7. Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1

Dogan I., AHMED M. A., YILDIZ A., Vatansever S.

INDIAN JOURNAL OF SURGICAL ONCOLOGY , sa.3, ss.484-488, 2024 (ESCI) Sürdürülebilir Kalkınma

8. Efficacy of Bevacizumab-Based Terapy in Patient With Metastatic or Recurrent Cervical Cancer: Real Life Data

KHANMAMMADOV N., Dogan I., okay n. s., Ugar M., Osmanova N., Saip P., et al.

Selçuk Tıp Dergisi , cilt.40, sa.2, ss.68-73, 2024 (TRDizin)

9. Hormonal Therapy in Pretreated Patients With Recurrent Ovary Granulosa Cell Tumor

DOĞAN İ., Aydın E., Topuz S., Saip P., Salihoglu M. Y., Aydiner A.

JOURNAL OF PHARMACY PRACTICE , cilt.37, sa.1, ss.146-150, 2024 (ESCI)

10. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer

Khanmammadov N., Doǧan I., Okay N. S., AZİZY A., Saip P., AYDINER A.

Medicine (United States) , cilt.103, sa.1, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

11. Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or-Allergic Metastatic Ovarian Cancer

Khanmammadov N., Doğan İ., Okay N. S., YILDIZ A., Khishigsuren B., AZİZY A., et al.

Turk Onkoloji Dergisi , cilt.39, sa.2, ss.176-182, 2024 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

12. Efficacy and safety of sorafenib in adult metastatic osteosarcoma patients

Dogan I., PAKSOY N., BAŞARAN M.

Journal of Cancer Research and Therapeutics , cilt.20, sa.3, ss.979-983, 2024 (SCI-Expanded, Scopus)

13. The Effect of Adjuvant Therapies for Recurrence in Stage I Breast Cancer Patients: A Single Centre Experience

Doğan İ., Khanmammadov N., Aydin E., PAKSOY N., Ferhatoğlu F., AK N., et al.

Turk Onkoloji Dergisi , cilt.39, sa.3, ss.257-264, 2024 (ESCI, Scopus, TRDizin)

14. Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients

Dogan I., Paksoy N., BAŞARAN M.

Journal of Cancer Research and Therapeutics , cilt.20, sa.1, ss.93-97, 2024 (SCI-Expanded, Scopus)

15. Outcomes of the patients with metastatic male breast cancer

Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.

Journal of Cancer Research and Therapeutics , cilt.20, sa.1, ss.98-102, 2024 (SCI-Expanded, Scopus)

16. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., et al.

Turkish Journal of Medical Sciences , cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded, Scopus, TRDizin)

17. Efficacy of Intrathecal Therapy In Breast Cancer Patients With Leptomeningeal Metastasis

Khanmammadov N., Dogan I., AHMED M. A., YILDIZ A., Nizam N., KHISHIGSUREN B., et al.

Eastern Journal of Medicine , cilt.29, sa.4, ss.503-508, 2024 (Scopus, TRDizin)

18. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.

Scientific Reports , cilt.13, sa.1, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients

DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center

Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoğlu F., Saip P., Aydiner A.

Medicine , cilt.102, sa.39, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

21. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors

DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.

Eurasian Journal of Pulmonology , cilt.25, sa.1, ss.27-32, 2023 (Hakemli Dergi)

22. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine

DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.

European Journal of Breast Health , cilt.19, sa.2, ss.128-133, 2023 (Scopus, TRDizin)

23. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., et al.

Cancers , cilt.15, sa.6, 2023 (SCI-Expanded, Scopus)

24. Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study

Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoǧlu F., AHMED M. A., Karaman S., et al.

Medicine (Spain) , cilt.102, sa.5, 2023 (Scopus) Sürdürülebilir Kalkınma

25. Clinicopathologic characteristics and prognostic factors in patients with male breast cancer: A single tertiary center experience

Dogan I., AYDIN E., AK N., ÖZKURT S., İBİŞ K., ŞÜKRÜOĞLU ERDOĞAN Ö., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.19, sa.7, ss.1887-1892, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

26. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience

TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., et al.

Journal of cancer research and therapeutics , cilt.19, sa.2, ss.253-258, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

27. **Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors**

Dogan I., Khanmammadov N., Yildiz A., AHMED M. A., Vatansever S., SAİP P. M., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.19, sa.7, ss.1945-1949, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

28. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma

DOĞAN İ., Iribas A., Ahmed M. A., Basaran M.

JOURNAL OF CHEMOTHERAPY , cilt.35, sa.4, ss.343-347, 2023 (SCI-Expanded)

29. High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience

PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., et al.

Medicine (United States) , cilt.101, sa.49, 2022 (SCI-Expanded, Scopus)

30. Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study

Yekeduz E., Dogan I., Kaya D. M., Ozgur I., UTKAN G., Vatansever S., et al.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.53, sa.4, ss.870-879, 2022 (ESCI, Scopus) Sürdürülebilir Kalkınma

31. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Erol C., Nahit Sendur M. A., Bilgetekin I., Garbioglu D. B., Hamdard J., Akbas S., et al.

Journal of cancer research and therapeutics , cilt.18, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

32. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., et al.

Medicine (United States) , cilt.101, sa.45, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

33. Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients

DOĞAN İ., Aydin E., Yazici H., Saip P.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.18, sa.4, ss.323-328, 2022 (ESCI, TRDizin)

34. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study

Dogan I., Ayhan M., Gurbuz M., Kucukarda A., Aydın E., ÜRÜN Y., et al.

MEDICINE , cilt.101, sa.35, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

35. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

Ozdemir O., Zengel B., Yildiz Y., Uluc B. O., ÇABUK D., Ozden E., et al.

ANTI-CANCER DRUGS , cilt.33, sa.7, ss.663-670, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

36. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors

DOĞAN İ., Tastekin D., Karabulut S., Sakar B.

JOURNAL OF DIGESTIVE DISEASES , cilt.23, ss.493-499, 2022 (SCI-Expanded, Scopus)

37. Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer

DOĞAN İ., Karabulut S., Tastekin D., Ferhatoglu F., Paksoy N., Sakar B.

JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN , cilt.32, sa.8, ss.1014-1019, 2022 (SCI-Expanded, Scopus)

38. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., et al.

MEDICINE , cilt.101, sa.34, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.

CLINICAL CANCER INVESTIGATION JOURNAL , sa.4, ss.5-9, 2022 (ESCI)

40. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.

Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.

CLINICAL CANCER INVESTIGATION JOURNAL , sa.3, ss.25-29, 2022 (ESCI)

42. The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer

Gurbuz M., DOĞAN İ., AKKUŞ E., ÖZAKINCI H., Tolunay P. K., KALACI E., et al.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , cilt.70, sa.2, ss.132-140, 2022 (ESCI, Scopus, TRDizin)

43. Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study

Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.37, sa.4, ss.478-483, 2022 (ESCI, Scopus, TRDizin)

44. Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib

Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydın E., Vatansever S., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.37, ss.413-418, 2022 (ESCI, Scopus)

45. Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up : FDG PET in recurrent colorectal CA.

ozkan Z. G., Has Simsek D., Kuyumcu S., Oflas M., Isik E. G., Dogan I., et al.

Annals of nuclear medicine , cilt.36, sa.1, ss.52-60, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

Ay S., Atci M. M., Arikan R., Dulgar O., Ozyukseler D. T., Paksoy N., et al.

JOURNAL OF CHEMOTHERAPY , cilt.34, sa.7, ss.465-471, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

47. Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey

Karabulut S., DOĞAN İ., USUL AFŞAR Ç., Karabulut M., Ak N., Duran A., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.1, ss.127-134, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

48. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

49. Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.

Ferhatoglu F., Paksoy N., Dogan I., Ak N., Pehlivan M., Ekenel M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

50. Efficacy of vincristine, irinotecan, and temozolomide (VIT) combination in adult patients with metastatic Ewing sarcoma.

Dogan I., Iribas A., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

51. Efficacy of temozolomide in pretreated patients with metastatic sarcoma.

Paksoy N., Dogan I., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded)

52. Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma.

Paksoy N., Dogan I., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded)

53. Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.

Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

54. Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.

Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

55. Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer

Dogan I., Aydin E., Khanmammadov N., Aydiner A., Saip P.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

56. Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.

Dogan I., Iribas A., Paksoy N., Ekenel M., Vatansever S., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

57. Outcomes of metastatic male breast cancer

Dogan I., Khanmammadov N., Aydiner A., Saip P.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

58. Comparison of clinicopathological features in BRCA-wild type and -mutated male breast cancer patients

Dogan I., Aydin E., Yazici H., Saip P.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

59. Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma

Naziye A. K., Paksoy N., Ferhatoglu F., Aydin E., Dogan I., Bektas E., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.36, ss.438-445, 2021 (ESCI)

60. Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.

Dogan I., Tastekin D., Karabulut S., Sakar B.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.3, 2021 (SCI-Expanded, Scopus)

61. A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.

Yekeduz E., Dogan I., AKBULUT H., Karabulut S., Utkan G., ÜRÜN Y.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.3, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 5

5. BAĞIŞIKLIK KONTROL NOKTASI İNHİBİTÖRLERİ: İRECIST, İRRC VE İRRECIST’İN PERFORMANSLARININ VE UYUMLARININ DEĞERLENDİRİLMESİ IMMUNE CHECKPOİNT İNHİBİTORS: ASSESSMENT OF THE PERFORMANCE AND THE AGREEMENT OF İRECIST, İRRC AND İRRECIST

Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.

41.Ulusal Radyoloji Kongresi, Antalya, Türkiye, 24 Ekim - 01 Kasım 2020, ss.205-206, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler